Water supplementation reduces copeptin and plasma glucose in adults with high copeptin: The H2O metabolism pilot study

Journal of Clinical Endocrinology and Metabolism

Volumn 104, Issue 6, 2019, Pages 1917-1925

  Enhorning, Sofia ^a   Brunkwall, Louise ^a   Tasevska, Irina ^a   Ericson, Ulrika ^a   Tholin, Jenny Persson ^a   Persson, Margaretha ^a   Lemetais, Guillaume ^b   Vanhaecke, Tiphaine ^b   Dolci, Alberto ^b   Perrier, Erica T ^b   Melander, Olle ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Danone Research   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COPEPTIN; GLUCOSE; WATER;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FLUID INTAKE; FLUID THERAPY; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HUMAN EXPERIMENT; HYDRATION; MALE; METABOLISM; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE; URINE OSMOLALITY; URINE VOLUME;

EID: 85063756741     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2018-02195     Document Type: Article

References (39)

1. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999;48(5):937-942.
2. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metare-gression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22(2): 233-240.
3. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52(1):112-119.
4. Balanescu S, Kopp P, Gaskill MB, Morgenthaler NG, Schindler C, Rutishauser J. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States. J Clin Endocrinol Metab. 2011;96(4):1046-1052.
5. Roussel R, Fezeu L, Marre M, Velho G, Fumeron F, Jungers P, Lantieri O, Balkau B, Bouby N, Bankir L, Bichet DG. Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab. 2014;99(12):4656-4663.
6. Enhorning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, Struck J, Morgenthaler NG, Bergmann A, Lindholm E, Groop L, Lyssenko V, Orho-Melander M, Newton-Cheh C, Melander O. Plasma copeptin and the risk of diabetes mellitus. Circulation. 2010;121(19):2102-2108.
7. Abbasi A, Corpeleijn E, Meijer E, Postmus D, Gansevoort RT, Gans RO, Struck J, Hillege HL, Stolk RP, Navis G, Bakker SJ. Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia. 2012;55(7): 1963-1970.
8. Wannamethee SG, Welsh P, Papacosta O, Lennon L, Whincup PH, Sattar N. Copeptin, insulin resistance, and risk of incident diabetes in older men. J Clin Endocrinol Metab. 2015;100(9): 3332-3339.
9. Enhorning S, Struck J, Wirfalt E, Hedblad B, Morgenthaler NG, Melander O. Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab. 2011;96(7):E1065-E1072.
10. Enhorning S, Bankir L, Bouby N, Struck J, Hedblad B, Persson M, Morgenthaler NG, Nilsson PM, Melander O. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmo Diet and Cancer Study cardiovascular cohort. Int J Obes. 2013;37(4):598-603.
11. Enhorning S, Hedblad B, Nilsson PM, Engstrom G, Melander O. Copeptin is an independent predictor of diabetic heart disease and death. Am Heart J. 2015;169:549-556 e541.
12. Tasevska I, Enhorning S, Persson M, Nilsson PM, Melander O. Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart. 2016;102(2):127-132.
13. Velho G, El Boustany R, Lefevre G, Mohammedi K, Fumeron F, Potier L, Bankir L, Bouby N, Hadjadj S, Marre M, Roussel R. Plasma copeptin, kidney outcomes, ischemic heart disease, and all-cause mortality in people with long-standing type 1 diabetes. Diabetes Care. 2016;39(12):2288-2295.
14. Taveau C, Chollet C, Waeckel L, Desposito D, Bichet DG, Arthus MF, Magnan C, Philippe E, Paradis V, Foufelle F, Hainault I, Enhorning S, Velho G, Roussel R, Bankir L, Melander O, Bouby N. Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia. 2015;58(5):1081-1090.
15. Roussel R, El Boustany R, Bouby N, Potier L, Fumeron F, Mohammedi K, Balkau B, Tichet J, Bankir L, Marre M, Velho G. Plasma copeptin, AVP gene variants, and incidence of type 2 diabetes in a cohort from the community. J Clin Endocrinol Metab. 2016;101(6):2432-2439.
16. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res. 2001;51(3):372-390.
17. Whitton PD, Rodrigues LM, Hems DA. Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions. Biochem J. 1978;176(3):893-898.
18. Keppens S, de Wulf H. The nature of the hepatic receptors involved in vasopressin-induced glycogenolysis. Biochim Biophys Acta. 1979;588(1):63-69.
19. Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu TA, Mori T, Tsujimoto G. The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Invest. 2004;113(2):302-309.
20. Antoni FA. Vasopressinergic control of pituitary adrenocortico-tropin secretion comes of age. Front Neuroendocrinol. 1993;14(2): 76-122.
21. Perraudin V, Delarue C, Lefebvre H, Contesse V, Kuhn JM, Vaudry H. Vasopressin stimulates cortisol secretion from human adreno-cortical tissue through activation of V1 receptors. J Clin Endocrinol Metab. 1993;76(6):1522-1528.
22. Abu-Basha EA, Yibchok-Anun S, Hsu WH. Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. Metabolism. 2002;51(9):1184-1190.
23. Spruce BA, McCulloch AJ, Burd J, Orskov H, Heaton A, Baylis PH, Alberti KG. The effect of vasopressin infusion on glucose metabolism in man. Clin Endocrinol (Oxf). 1985;22(4):463-468.
24. Perrier E, Vergne S, Klein A, Poupin M, Rondeau P, Le Bellego L, Armstrong LE, Lang F, Stookey J, Tack I. Hydration biomarkers in free-living adults with different levels of habitual fluid consumption. Br J Nutr. 2013;109(9):1678-1687.
25. Johnson EC, Munoz CX, Jimenez L, Le Bellego L, Kupchak BR, Kraemer WJ, Casa DJ, Maresh CM, Armstrong LE. Hormonal and thirst modulated maintenance of fluid balance in young women with different levels of habitual fluid consumption. Nutrients. 2016; 8(5):8.
26. Lemetais G, Melander O, Vecchio M, Bottin JH, Enhorning S, Perrier ET. Effect of increased water intake on plasma copeptin in healthy adults. Eur J Nutr. 2017;57(5):1883-1890.
27. Roussel R, Fezeu L, Bouby N, Balkau B, Lantieri O, Alhenc-Gelas F, Marre M, Bankir L; D.E.S.I.R. Study Group. Low water intake and risk for new-onset hyperglycemia. Diabetes Care. 2011;34(12): 2551-2554.
28. Enhorning S, Tasevska I, Roussel R, Bouby N, Persson M, Burri P, Bankir L, Melander O. Effects of hydration on plasma copeptin, glycemia and gluco-regulatory hormones: a water intervention in humans. Eur J Nutr. 2019;58(1):315-324.
29. Ottosson F, Brunkwall L, Ericson U, Nilsson PM, Almgren P, Fernandez C, Melander O, Orho-Melander M. Connection between BMI related plasma metabolite profile and gut microbiota. J Clin Endocrinol Metab. 2018;103(4):1491-1501.
30. Armstrong LE, Maresh CM, Castellani JW, Bergeron MF, Kenefick RW, LaGasse KE, Riebe D. Urinary indices of hydration status. Int J Sport Nutr. 1994;4(3):265-279.
31. Nybacka S, Berteus Forslund H, Wirfalt E, Larsson I, Ericson U, Warensjo Lemming E, Bergstrom G, Hedblad B, Winkvist A, Lindroos AK. Comparison of a web-based food record tool and a food-frequency questionnaire and objective validation using the doubly labelled water technique in a Swedish middle-aged population. J Nutr Sci. 2016;5:e39.
32. Clark WF, Sontrop JM, Huang SH, Gallo K, Moist L, House AA, Weir MA, Garg AX. The chronic kidney disease Water Intake Trial (WIT): results from the pilot randomised controlled trial. BMJ Open. 2013;3(12):e003666.
33. Roussel R, Matallah N, Bouby N, El Boustany R, Potier L, Fumeron F, Mohammedi K, Balkau B, Marre M, Bankir L, Velho G. Plasma copeptin and decline in renal function in a cohort from the community: the prospective D.E.S.I.R. study. Am J Nephrol. 2015;42(2):107-114.
34. Tasevska I, Enhorning S, Christensson A, Persson M, Nilsson PM, Melander O. Increased levels of copeptin, a surrogate marker of arginine vasopressin, are associated with an increased risk of chronic kidney disease in a general population. Am J Nephrol. 2016;44(1):22-28.
35. Jochberger S, Dorler J, Luckner G, Mayr VD, Wenzel V, Ulmer H, Morgenthaler NG, Hasibeder WR, Dunser MW. The vasopressin and copeptin response to infection, severe sepsis, and septic shock. Crit Care Med. 2009;37(2):476-482.
36. Stoiser B, Mortl D, Hulsmann M, Berger R, Struck J, Morgenthaler NG, Bergmann A, Pacher R. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest. 2006;36(11):771-778.
37. Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM, Roth A, Bickel C, Baldus S, Sinning CR, Wild PS, Lubos E, Peetz D, Kunde J, Hartmann O, Bergmann A, Post F, Lackner KJ, Genth-Zotz S, Nicaud V, Tiret L, Munzel TF, Blankenberg S. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol. 2010;55(19):2096-2106.
38. Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock. 2007;28(2):219-226.
39. EFSA Panel on Dietetic Products, Nutrition, and Allergies. Scientific opinion on dietary reference values for water. EFSA J. 2010;8: 1459.